ES2272096T3 - Purificacion de compuestos ciclopeptidicos de equinocandina. - Google Patents
Purificacion de compuestos ciclopeptidicos de equinocandina. Download PDFInfo
- Publication number
- ES2272096T3 ES2272096T3 ES99965156T ES99965156T ES2272096T3 ES 2272096 T3 ES2272096 T3 ES 2272096T3 ES 99965156 T ES99965156 T ES 99965156T ES 99965156 T ES99965156 T ES 99965156T ES 2272096 T3 ES2272096 T3 ES 2272096T3
- Authority
- ES
- Spain
- Prior art keywords
- acetic acid
- echinocandin
- procedure
- product
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 42
- 238000000746 purification Methods 0.000 title claims description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 152
- 238000000034 method Methods 0.000 claims abstract description 55
- 239000000203 mixture Substances 0.000 claims abstract description 25
- 239000000047 product Substances 0.000 claims abstract description 25
- 238000000855 fermentation Methods 0.000 claims abstract description 24
- 230000004151 fermentation Effects 0.000 claims abstract description 24
- 239000006227 byproduct Substances 0.000 claims abstract description 17
- 125000003277 amino group Chemical group 0.000 claims abstract description 15
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 13
- 239000012501 chromatography medium Substances 0.000 claims abstract description 9
- 238000010828 elution Methods 0.000 claims description 36
- 108010049047 Echinocandins Proteins 0.000 claims description 31
- 229920005989 resin Polymers 0.000 claims description 18
- 239000011347 resin Substances 0.000 claims description 18
- 239000011148 porous material Substances 0.000 claims description 13
- 239000002245 particle Substances 0.000 claims description 12
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 8
- 230000002441 reversible effect Effects 0.000 claims description 8
- 238000000926 separation method Methods 0.000 claims description 8
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 claims description 6
- 238000011084 recovery Methods 0.000 claims description 6
- 238000004366 reverse phase liquid chromatography Methods 0.000 claims description 5
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 claims description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 4
- 229920000620 organic polymer Polymers 0.000 claims description 4
- 238000001179 sorption measurement Methods 0.000 claims description 4
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical group C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 125000003011 styrenyl group Chemical group [H]\C(*)=C(/[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 235000010633 broth Nutrition 0.000 abstract description 12
- 108010069514 Cyclic Peptides Proteins 0.000 abstract description 7
- 102000001189 Cyclic Peptides Human genes 0.000 abstract description 7
- 230000008569 process Effects 0.000 abstract description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 74
- -1 sporiofungin A Chemical compound 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 229910004373 HOAc Inorganic materials 0.000 description 11
- 108010062092 echinocandin B Proteins 0.000 description 10
- FAUOJMHVEYMQQG-HVYQDZECSA-N echinocandin B Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCC\C=C/C\C=C/CCCCC)[C@@H](C)O)=CC=C(O)C=C1 FAUOJMHVEYMQQG-HVYQDZECSA-N 0.000 description 9
- 238000004007 reversed phase HPLC Methods 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 7
- 229930014626 natural product Natural products 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- SWWQQSDRUYSMAR-UHFFFAOYSA-N 1-[(4-hydroxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline-6,7-diol;hydrochloride Chemical group Cl.C1=CC(O)=CC=C1CC1C2=CC(O)=C(O)C=C2CCN1 SWWQQSDRUYSMAR-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 239000003607 modifier Substances 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- XYFCNXWJFGUGBZ-UHFFFAOYSA-N oxathiecane 2,2-dioxide Chemical compound O=S1(=O)CCCCCCCCO1 XYFCNXWJFGUGBZ-UHFFFAOYSA-N 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 3
- 229940001584 sodium metabisulfite Drugs 0.000 description 3
- 235000010262 sodium metabisulphite Nutrition 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- KAPLTEIQCKDUAT-UHFFFAOYSA-N ac1la431 Chemical compound N1C(=O)C2CC(O)CN2C(=O)C(C(C)O)NC(=O)C(NC(=O)CCCCCCCCCCCCCCC)CC(O)C(O)NC(=O)C2C(O)C(C)CN2C(=O)C(C(O)CC(N)=O)NC(=O)C1C(O)C(O)C1=CC=C(O)C(OS(O)(=O)=O)=C1 KAPLTEIQCKDUAT-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000020176 deacylation Effects 0.000 description 2
- 238000005947 deacylation reaction Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- UJTTUOLQLCQZEA-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-(4-hydroxybutyl)carbamate Chemical compound C1=CC=C2C(COC(=O)NCCCCO)C3=CC=CC=C3C2=C1 UJTTUOLQLCQZEA-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000187840 Actinoplanes utahensis Species 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- DFQUSLQYURJBIT-MFKXNLKNSA-N C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCCC(C)CC(C)CC)[C@H](O)CC(N)=O)=CC=C(O)C=C1 Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCCC(C)CC(C)CC)[C@H](O)CC(N)=O)=CC=C(O)C=C1 DFQUSLQYURJBIT-MFKXNLKNSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- WUPSJTQKGFMDON-UHFFFAOYSA-N Mulundocandin Natural products N1C(=O)C2CC(O)CN2C(=O)C(C(C)O)NC(=O)C(NC(=O)CCCCCCCCCCC(C)CC)CC(O)C(O)NC(=O)C2C(O)C(C)CN2C(=O)C(CO)NC(=O)C1C(O)C(O)C1=CC=C(O)C=C1 WUPSJTQKGFMDON-UHFFFAOYSA-N 0.000 description 1
- WUPSJTQKGFMDON-FUMJLYDLSA-N N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-15-[(1R)-1-hydroxyethyl]-3-(hydroxymethyl)-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-12-methyltetradecanamide Chemical compound CCC(C)CCCCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)C(O)c1ccc(O)cc1 WUPSJTQKGFMDON-FUMJLYDLSA-N 0.000 description 1
- CWLQUGTUXBXTLF-UHFFFAOYSA-N N-methyl-L-proline monohydrate Natural products CN1CCCC1C(O)=O CWLQUGTUXBXTLF-UHFFFAOYSA-N 0.000 description 1
- CWLQUGTUXBXTLF-YFKPBYRVSA-N N-methylproline Chemical compound CN1CCC[C@H]1C(O)=O CWLQUGTUXBXTLF-YFKPBYRVSA-N 0.000 description 1
- 229910004727 OSO3H Inorganic materials 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108010045495 WF 11899A Proteins 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 108010081349 aculeacin A Proteins 0.000 description 1
- FBCLKBXYZRAXNA-PDIPHZEPSA-N aculeacin A Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCCCCCCCCC)[C@H](O)CC(N)=O)=CC=C(O)C=C1 FBCLKBXYZRAXNA-PDIPHZEPSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000002431 aminoalkoxy group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012045 crude solution Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 108010062096 echinocandin C Proteins 0.000 description 1
- NZZDHXBKVFENNY-YBPCKFEPSA-N echinocandin c Chemical compound C([C@@H](O)[C@H]1C(=O)N[C@H](C(=O)N2C[C@H](C)[C@H](O)[C@H]2C(=O)N[C@H](O)[C@H](O)C[C@@H](C(N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)N1)[C@@H](C)O)=O)NC(=O)CCCCCCC\C=C/C\C=C/CCCCC)[C@@H](C)O)C1=CC=C(O)C=C1 NZZDHXBKVFENNY-YBPCKFEPSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 125000005191 hydroxyalkylamino group Chemical group 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108010084578 mulundocandin Proteins 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 108010023461 pneumocandin A(0) Proteins 0.000 description 1
- 108010016309 pneumocandin B(0) Proteins 0.000 description 1
- DQXPFAADCTZLNL-FXDJFZINSA-N pneumocandin B0 Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CC(N)=O)=CC=C(O)C=C1 DQXPFAADCTZLNL-FXDJFZINSA-N 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- OGNAOIGAPPSUMG-UHFFFAOYSA-N spiro[2.2]pentane Chemical compound C1CC11CC1 OGNAOIGAPPSUMG-UHFFFAOYSA-N 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 239000010891 toxic waste Substances 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11152498P | 1998-12-09 | 1998-12-09 | |
| US111524P | 1998-12-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2272096T3 true ES2272096T3 (es) | 2007-04-16 |
Family
ID=22339024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES99965156T Expired - Lifetime ES2272096T3 (es) | 1998-12-09 | 1999-12-08 | Purificacion de compuestos ciclopeptidicos de equinocandina. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6506726B1 (https=) |
| EP (1) | EP1137663B1 (https=) |
| JP (1) | JP2003511345A (https=) |
| KR (1) | KR20010101151A (https=) |
| CN (1) | CN1337968A (https=) |
| AT (1) | ATE338059T1 (https=) |
| AU (1) | AU766091B2 (https=) |
| BR (1) | BR9916101A (https=) |
| CA (1) | CA2353930A1 (https=) |
| DE (1) | DE69933046T2 (https=) |
| DK (1) | DK1137663T3 (https=) |
| ES (1) | ES2272096T3 (https=) |
| IL (1) | IL143563A0 (https=) |
| PT (1) | PT1137663E (https=) |
| RU (1) | RU2001118849A (https=) |
| WO (1) | WO2000034315A2 (https=) |
| ZA (1) | ZA200104621B (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6743777B1 (en) * | 1992-03-19 | 2004-06-01 | Eli Lilly And Company | Cyclic peptide antifungal agents and process for preparation thereof |
| KR20020003864A (ko) * | 1999-03-03 | 2002-01-15 | 피터 지. 스트링거 | 에키노칸딘/탄수화물 착물 |
| AU767956B2 (en) | 1999-03-03 | 2003-11-27 | Eli Lilly And Company | Formation and anion-exchange of crystalline echinocandin ammonium salts |
| EP1582204B1 (en) * | 1999-03-03 | 2013-09-25 | Eli Lilly & Company | Echinocandin pharmaceutical formulations containing micelle-forming surfactants |
| WO2000051567A1 (en) | 1999-03-03 | 2000-09-08 | Eli Lilly And Company | Processes for making pharmaceutical oral ecb formulations and compositions |
| US6991800B2 (en) * | 2002-06-13 | 2006-01-31 | Vicuron Pharmaceuticals Inc. | Antifungal parenteral products |
| RU2411959C2 (ru) * | 2004-06-29 | 2011-02-20 | Релайанс Лайф Сайенсиз Пвт Лтд | Способ получения безопасных в вирусном отношении биологических текучих сред |
| DE102004060750A1 (de) * | 2004-12-15 | 2006-07-13 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Deacylierung von Lipopeptiden |
| TW200826957A (en) | 2006-10-16 | 2008-07-01 | Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag | Purification processes for echinocandin-type compounds |
| US9394340B2 (en) | 2009-03-24 | 2016-07-19 | Cadila Healthcare Limited | Purification process for lipopeptides |
| CN102219832B (zh) * | 2010-04-15 | 2013-08-21 | 上海天伟生物制药有限公司 | 一种氮杂环六肽或其盐的纯化方法 |
| CN102336817B (zh) * | 2010-07-16 | 2016-06-15 | 浙江震元制药有限公司 | 棘球白素b母核的分离方法 |
| RU2535489C1 (ru) * | 2010-09-29 | 2014-12-10 | Шанхай Техвелл Биофармасьютикал Ко., Лтд. | Способ очистки циклолипопептидных соединений или их солей |
| US8877777B2 (en) * | 2010-09-30 | 2014-11-04 | Shanghai Techwell Biopharmaceutical Co., Ltd. | Process for purifying cyclolipopeptide compounds or the salts thereof |
| CN102153616A (zh) * | 2010-12-27 | 2011-08-17 | 浙江海正药业股份有限公司 | 一种环己肽类化合物及其盐的分离纯化方法 |
| ES2645074T3 (es) | 2011-03-03 | 2017-12-04 | Cidara Therapeutics, Inc. | Agentes antifúngicos y sus usos |
| BR112013026420A2 (pt) * | 2011-04-20 | 2020-11-03 | Xellia Pharmaceuticals Aps | método de produção de um sal de micafungina farmaceuticamente aceitável |
| CN102952178B (zh) * | 2011-08-24 | 2016-04-27 | 华北制药集团新药研究开发有限责任公司 | 一种高纯度棘白霉素类化合物的制备方法 |
| RU2639483C2 (ru) | 2012-03-19 | 2017-12-21 | Сидара Терапьютикс, Инк. | Режимы дозирования для соединений класса эхинокандинов |
| CN103483427A (zh) * | 2012-06-09 | 2014-01-01 | 浙江海正药业股份有限公司 | 一种棘白菌素类化合物的纯化方法 |
| CN103910783B (zh) * | 2014-04-23 | 2016-07-06 | 华北制药集团新药研究开发有限责任公司 | 一种高纯度棘白霉素b母核的制备方法 |
| ES2694561T3 (es) | 2015-02-23 | 2018-12-21 | Selectchemie Ag | Composición de anidulafungina |
| CN108883152A (zh) | 2016-01-08 | 2018-11-23 | 奇达拉治疗公司 | 防止和治疗肺孢子虫感染的方法 |
| WO2017161016A1 (en) | 2016-03-16 | 2017-09-21 | Cidara Therapeutics, Inc. | Dosing regimens for treatment of fungal infections |
| CN106248857A (zh) * | 2016-07-15 | 2016-12-21 | 广西医科大学 | 利用薄层层析快速检测植物环肽的方法 |
| US11197909B2 (en) | 2017-07-12 | 2021-12-14 | Cidara Therapeutics, Inc. | Compositions and methods for the treatment of fungal infections |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4320052A (en) | 1979-12-13 | 1982-03-16 | Eli Lilly And Company | Derivatives of A-30912A nucleus |
| US4293489A (en) | 1979-12-13 | 1981-10-06 | Eli Lilly And Company | Derivatives of A-30912A nucleus |
| US4304716A (en) | 1979-12-13 | 1981-12-08 | Eli Lilly And Company | S 31794/F-1 Nucleus |
| US4293482A (en) | 1979-12-13 | 1981-10-06 | Eli Lilly And Company | A-30912A Nucleus |
| US4874843A (en) | 1987-12-03 | 1989-10-17 | Eli Lilly And Company | Chromatographic purification process |
| EP0294990A3 (en) * | 1987-06-10 | 1990-05-09 | Eli Lilly And Company | Chromatographic purification process |
| US5166135A (en) | 1988-09-12 | 1992-11-24 | Merck & Company, Inc. | Method for the control of pneumocystis carinii |
| DK173802B1 (da) | 1988-09-12 | 2001-11-05 | Merck & Co Inc | Præparat til behandling af Pneumocystis carinii infeksioner og anvendelse af et cyclohexapeptid til fremstilling af et lægemiddel mod Pneumocystis carinii infektioner |
| US5310726A (en) | 1990-03-19 | 1994-05-10 | Merck & Co., Inc. | Lipopeptide compounds |
| ES2089133T3 (es) | 1990-06-07 | 1996-10-01 | Lilly Co Eli | Desacilasa de lipopeptidos. |
| IE990233A1 (en) | 1990-06-18 | 2000-11-15 | Fujisawa Pharmaceutical Co | New Polypeptide Compound and a Process for Preparation thereof |
| US5965525A (en) | 1992-03-19 | 1999-10-12 | Eli Lilly And Company | Cyclic peptide antifungal agents |
| NZ247149A (en) | 1992-03-19 | 1996-10-28 | Lilly Co Eli | Cyclic peptide antifungal agents and compositions thereof |
| US5541160A (en) | 1994-04-04 | 1996-07-30 | Merck & Co., Inc. | Antifungal and anti-pneumocystis compounds, compositions containing such compounds, and methods of use |
| US5646111A (en) | 1995-04-07 | 1997-07-08 | Eli Lilly And Company | Cyclic peptide antifungal Agents |
| US5652213A (en) | 1995-05-26 | 1997-07-29 | Eli Lilly And Company | Cyclic peptide antifungal agents |
| US5629290A (en) | 1995-05-26 | 1997-05-13 | Eli Lilly And Company | Cyclic peptide antifungal agents |
| US5618787A (en) | 1995-05-26 | 1997-04-08 | Eli Lilly And Company | Cyclic peptide antifungal agents |
| US5786325A (en) | 1995-05-26 | 1998-07-28 | Eli Lilly And Company | Cyclic peptide antifungal agents and methods of making and using |
| US5629289A (en) | 1995-07-25 | 1997-05-13 | Eli Lilly And Company | Cyclic peptide antifungal agents |
| WO1997027864A1 (en) | 1996-02-01 | 1997-08-07 | Eli Lilly And Company | Cyclic peptide antifungal agents |
| US5696084A (en) | 1996-08-16 | 1997-12-09 | Abbott Laboratories | Amino-lipopetide antifungal agents |
| WO1999006062A1 (en) | 1997-08-04 | 1999-02-11 | Eli Lilly And Company | Cyclic peptide antifungal agents |
| CA2255140A1 (en) | 1997-12-23 | 1999-06-23 | Eli Lilly And Company | Echinocandin binding domain of 1,3-.beta.-glucan synthase |
| US6323176B1 (en) | 1998-02-25 | 2001-11-27 | Eli Lilly And Company | Cyclic peptide antifungal agents |
| ES2233070T3 (es) | 1998-08-20 | 2005-06-01 | ELI LILLY & COMPANY | Sintesis de analogos peptidicos ciclicos modificados en el anillo. |
| WO2000012540A1 (en) | 1998-08-28 | 2000-03-09 | Eli Lilly And Company | Reversible boronate complexes of 1,2-cis-diol cyclic-peptides |
| AU1517900A (en) | 1998-10-28 | 2000-05-15 | Eli Lilly And Company | Photochemical process for making 1-deoxy-2-keto derivatives |
| JP2002532513A (ja) | 1998-12-16 | 2002-10-02 | イーライ リリー アンド カンパニー | 糖置換基を有する環式ペプチド抗真菌剤 |
| AU767357B2 (en) | 1998-12-16 | 2003-11-06 | Eli Lilly And Company | Cyclic peptide antifungal agents |
| AU767956B2 (en) | 1999-03-03 | 2003-11-27 | Eli Lilly And Company | Formation and anion-exchange of crystalline echinocandin ammonium salts |
| WO2000051567A1 (en) | 1999-03-03 | 2000-09-08 | Eli Lilly And Company | Processes for making pharmaceutical oral ecb formulations and compositions |
| KR20020003864A (ko) | 1999-03-03 | 2002-01-15 | 피터 지. 스트링거 | 에키노칸딘/탄수화물 착물 |
| EP1582204B1 (en) | 1999-03-03 | 2013-09-25 | Eli Lilly & Company | Echinocandin pharmaceutical formulations containing micelle-forming surfactants |
-
1999
- 1999-12-08 DE DE69933046T patent/DE69933046T2/de not_active Expired - Fee Related
- 1999-12-08 US US09/857,924 patent/US6506726B1/en not_active Expired - Fee Related
- 1999-12-08 WO PCT/US1999/029008 patent/WO2000034315A2/en not_active Ceased
- 1999-12-08 RU RU2001118849/04A patent/RU2001118849A/ru not_active Application Discontinuation
- 1999-12-08 ES ES99965156T patent/ES2272096T3/es not_active Expired - Lifetime
- 1999-12-08 CN CN99815515A patent/CN1337968A/zh active Pending
- 1999-12-08 BR BR9916101-0A patent/BR9916101A/pt not_active IP Right Cessation
- 1999-12-08 PT PT99965156T patent/PT1137663E/pt unknown
- 1999-12-08 EP EP99965156A patent/EP1137663B1/en not_active Expired - Lifetime
- 1999-12-08 DK DK99965156T patent/DK1137663T3/da active
- 1999-12-08 KR KR1020017007161A patent/KR20010101151A/ko not_active Withdrawn
- 1999-12-08 AT AT99965156T patent/ATE338059T1/de not_active IP Right Cessation
- 1999-12-08 IL IL14356399A patent/IL143563A0/xx unknown
- 1999-12-08 AU AU31132/00A patent/AU766091B2/en not_active Ceased
- 1999-12-08 JP JP2000586757A patent/JP2003511345A/ja not_active Abandoned
- 1999-12-08 CA CA002353930A patent/CA2353930A1/en not_active Abandoned
-
2001
- 2001-06-06 ZA ZA200104621A patent/ZA200104621B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000034315A3 (en) | 2000-12-28 |
| BR9916101A (pt) | 2002-06-04 |
| DE69933046T2 (de) | 2007-09-13 |
| PT1137663E (pt) | 2006-12-29 |
| WO2000034315A8 (en) | 2000-10-26 |
| EP1137663A2 (en) | 2001-10-04 |
| RU2001118849A (ru) | 2003-08-10 |
| JP2003511345A (ja) | 2003-03-25 |
| AU3113200A (en) | 2000-06-26 |
| CA2353930A1 (en) | 2000-06-15 |
| EP1137663B1 (en) | 2006-08-30 |
| KR20010101151A (ko) | 2001-11-14 |
| ZA200104621B (en) | 2002-06-06 |
| IL143563A0 (en) | 2002-04-21 |
| ATE338059T1 (de) | 2006-09-15 |
| AU766091B2 (en) | 2003-10-09 |
| DK1137663T3 (da) | 2007-01-08 |
| WO2000034315A2 (en) | 2000-06-15 |
| US6506726B1 (en) | 2003-01-14 |
| CN1337968A (zh) | 2002-02-27 |
| DE69933046D1 (de) | 2006-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2272096T3 (es) | Purificacion de compuestos ciclopeptidicos de equinocandina. | |
| JP4063497B2 (ja) | エキノカンジンアンモニウム塩結晶の形成およびアニオン交換 | |
| CA1315229C (en) | Chromatographic purification process | |
| KR960002868B1 (ko) | 글리코펩티드 항생물질의 회수 방법 | |
| JPS6038389A (ja) | 精製したバンコマイシン群抗生物質の製法 | |
| US4584400A (en) | Refining phenylalanine | |
| Berkecz et al. | LC enantioseparation of β-lactam and β-amino acid stereoisomers and a comparison of macrocyclic glycopeptide-and β-cyclodextrin-based columns | |
| AU613640B2 (en) | Chromatographic purification process | |
| Müller et al. | Synthesis of N‐carboxyalkyl and N‐aminoalkyl functionalized dipeptide building units for the assembly of backbone cyclic peptides | |
| Peyrin et al. | Chiral discrimination of N-(dansyl)-DL-amino acids on human serum albumin stationary phase: effect of a mobile phase modifier | |
| CA2210987C (en) | Chromatographic purification of vancomycin hydrochloride by the use of preparative hplc | |
| MXPA01005688A (en) | Purification of echinocandin cyclopeptide compounds | |
| AU2004200026A1 (en) | Purification of echinocandin cyclopeptide compounds | |
| AU2004200741A1 (en) | Formation and anion-exchange of crystalline echinocandin ammonium salts | |
| MXPA01008787A (en) | Formation and anion-exchange of crystalline echinocandin ammonium salts | |
| JPH02178288A (ja) | ３―ヒドロキシメチル―７―アミノセフエムカルボン酸の精製法 | |
| JPS6348262A (ja) | 活性炭に吸着したｌ−トリプトフアンの溶離方法 | |
| Reissmann | B. MuÈ ller D. Besser P. KleinwaÈchter O. Arad | |
| Fisher et al. | AMBERCHROM PROFILE HPR10 Improving Performance for Peptide Purification. | |
| JPS6052753B2 (ja) | ７−アミノセフエム化合物の精製法 |